Young-Ho Lee
Directeur Général chez Immunique Co. Ltd.
Postes actifs de Young-Ho Lee
Sociétés | Poste | Début | Fin |
---|---|---|---|
Hanyang University | Corporate Officer/Principal | - | - |
Immunique Co. Ltd.
Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Directeur Général | - | - |
Historique de carrière de Young-Ho Lee
Anciens postes connus de Young-Ho Lee
Sociétés | Poste | Début | Fin |
---|---|---|---|
NANOENTEK, INC. | Directeur/Membre du Conseil | 24/03/2022 | 08/09/2023 |
Independent Dir/Board Member | 24/03/2022 | 08/09/2023 |
Formation de Young-Ho Lee
Hanyang University | Doctorate Degree |
Statistiques
Internationale
Corée du Sud | 4 |
Opérationnelle
Director/Board Member | 1 |
Independent Dir/Board Member | 1 |
Doctorate Degree | 1 |
Sectorielle
Health Technology | 2 |
Consumer Services | 2 |
Commercial Services | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
NANOENTEK, INC. | Health Technology |
Entreprise privées | 1 |
---|---|
Immunique Co. Ltd.
Immunique Co. Ltd. Miscellaneous Commercial ServicesCommercial Services Immunique Co. Ltd. is a South Korean research company that develops treatments for autoimmune diseases and cancer using immune cells derived from donated blood, such as regulatory T cells and natural killer cells. The company is based in Seongnam-si, South Korea. The company aims to become a leader in the immune cell therapy market. Graft-versus-host disease (GvHD) is a fatal condition that occurs when healthy lymphocytes (mainly T cells) from a blood transfusion are considered foreign by the recipient's body and cause severe side effects in vital organs. The CEO of the company is Young-Ho Lee. | Commercial Services |
- Bourse
- Insiders
- Young-Ho Lee
- Expérience